First Look Analysts Research Calls for Thursday, January 19
This report was sent to Briefing.com subscribers earlier today. Upgrades: > CureVac (CVAC) upgraded to Buy from Neutral at UBS; tgt raised to $18 Downgrades: > Cognizant Tech (CTSH) downgraded to Underperform from Market Perform at MoffettNathanson; tgt lowered to…
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> CureVac (CVAC) upgraded to Buy from Neutral at UBS; tgt raised to $18
Downgrades:
> Cognizant Tech (CTSH) downgraded to Underperform from Market Perform at MoffettNathanson; tgt lowered to $60
> DXC Technology (DXC) downgraded to Underperform from Market Perform at MoffettNathanson; tgt lowered to $28
Others:
> Alpine Immune Sciences (ALPN) initiated with an Overweight at Morgan Stanley; tgt $17
> CF Industries (CF) initiated with an Overweight at Wells Fargo; tgt $110
> Corteva (CTVA) initiated with an Overweight at Wells Fargo; tgt $78
> FMC Corp (FMC) assumed with an Overweight at Wells Fargo; tgt $148
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.